IRONWOOD PHARMACEUTICALS INC (IRWD) Form 10-Q — Aug 6, 2026
Ironwood Pharmaceuticals reported Q2 2026 revenue of $113.0 million, up $27.8 million from $85.2 million a year earlier, driven primarily by a $24.4 million increase in its share of LINZESS U.S. net profits on higher net price and prescription demand. Net income for the quarter was $51.3 million, or $0.31 per diluted share, versus $23.6 million, or $0.14, in Q2 2025. For the first six months of 2026, revenue reached $219.5 million and net income was $92.1 million ($0.55 diluted) versus a $13.8 million loss a year ago, with operating cash flow of $63.4 million.
Key figures
- Eps
- 0.31
- Revenue
- 113041000
- Net Income
- 51291000
- Total Debt
- 385000000
- Revenue Yoy
- +$27.8 million vs Q2 2025 ($85.2 million); +$93.2 million vs six months 2025 ($126.4 million)
- Total Assets
- 285128000
- Cash Position
- 79127000
- Shares Outstanding
- 165239947
- Six Month Revenue
- 219547000
- Abbvie Receivable
- 112200000
- Revolver Maturity
- December 31, 2028
- Six Month Net Income
- 92064000
- Accumulated Deficit
- 1581654000
- Six Month Diluted Eps
- 0.55
- Q2 Prior Year Net Income
- 23599000
- Q2 Prior Year Diluted Eps
- 0.14
- Revolving Credit Capacity
- 550000000
- Ferring Settlement Remaining
- 5000000
- Operating Cash Flow Six Months
- 63397000
- Grand Life Sciences Milestones
- 90000000
- Convertible Notes Repaid June2026
- 200000000
- Linzess Us Profit Share Increase Q2
- 24400000
- Abbvie Expanded Territory Milestones
- 42500000
Price after filing
Close on the filing date to close N calendar days later (from $4.31). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.